Pyrosequencing AB
This article was originally published in The Gray Sheet
Executive Summary
Positive clinical trial results for rapid DNA-based prenatal test for Down Syndrome (trisomy 21) lead to expanded R&D agreement with University of Geneva to include diagnostic tests for other trisomies, such as testing at the 18, 13, X and Y chromosomes. Announced May 7, expansion of the 2001 deal comprises genetic analysis and test development using Pyrosequencing technology...
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.